Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Respiratory Investigation|November 23, 2020
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trialArata Azuma, Lorinda Chung, Digambar Behera, et al.
Clinical and Experimental Rheumatology|July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
The European Respiratory Journal|August 30, 2022
Nintedanib in children and adolescents with fibrosing interstitial lung diseasesRobin Deterding, Lisa R Young, Emily M DeBoer, et al.
The New England Journal of Medicine|May 22, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung DiseaseOliver Distler, Kristin B Highland, Martina Gahlemann, et al.
Pediatric Pulmonology|January 30, 2024
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approachToby M Maher, Kevin K Brown, Steven Cunningham, et al.
Pediatric Pulmonology|June 22, 2026
Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ONRobin Deterding, Lisa R Young, Emily M DeBoer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 13, 2021
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness ScoreMasataka Kuwana, Yannick Allanore, Christopher P Denton, et al.
BMJ Open|December 17, 2020
Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborationsAnnelise Roennow, Maureen Sauvé, Joep Welling, et al.
The Lancet. Respiratory Medicine|January 7, 2021
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trialKristin B Highland, Oliver Distler, Masataka Kuwana, et al.
Pageof 2